Publications
Detailed Information
Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to < 18 years of age: A prospective, open-label, multi-center trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Chi-Eun | - |
dc.contributor.author | Lee, Jina | - |
dc.contributor.author | Kang, Jin-Han | - |
dc.contributor.author | Hong, Young-Jin | - |
dc.contributor.author | Cheong, Hee-Jin | - |
dc.contributor.author | Kim, Sang-Hoon | - |
dc.contributor.author | Lee, Hoan-Jong | - |
dc.contributor.author | Ahn, Young-Joo | - |
dc.contributor.author | Kim, Yun-Kyung | - |
dc.date.accessioned | 2012-06-12T04:48:58Z | - |
dc.date.available | 2012-06-12T04:48:58Z | - |
dc.date.issued | 2010-08-16 | - |
dc.identifier.citation | VACCINE; Vol.28 36; 5857-5863 | ko_KR |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://hdl.handle.net/10371/76999 | - |
dc.description.abstract | This study was conducted to determine the immunogenicity and safety of an inactivated split-virus influenza A/H1N1 vaccine in healthy Korean children from 6 months to <18 years of age. The immunization schedule consisted of two vaccinations, 21 days apart. The unadjuvanted vaccine contained 7.5 mu g (subjects 6 months to <3 years of age) or 15 mu g (subjects 3 to <18 years of age) of hemagglutinin antigen per dose. A total of 251 subjects were enrolled and 248 and 242 subjects, respectively, were included in the post-first dose and post-second dose immunogenicity evaluations conducted on a per protocol basis. By day 21, after the first dose, hemagglutination-inhibition titers of 1:40 or more were observed in 5.9% of subjects 6 months to <3 years of age, 34.9% of subjects 3 to <9 years of age and 81.4% of subjects 9-18 years of age. By day 21 after the second dose, the titer had been achieved 55.9%, 69.5% and 90.5%, respectively. No vaccination-related serious adverse events were observed. A single 15-mu g dose of vaccine was highly immunogenic in subjects equal to or more than 9 years of age. However, a two-dose regimen is needed to produce potentially protective antibody titers in younger children. (C) 2010 Elsevier Ltd. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCI LTD | ko_KR |
dc.subject | H1N1 virus | ko_KR |
dc.subject | Pandemic | ko_KR |
dc.subject | Influenza vaccine | ko_KR |
dc.title | Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to < 18 years of age: A prospective, open-label, multi-center trial | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 오지은 | - |
dc.contributor.AlternativeAuthor | 이지나 | - |
dc.contributor.AlternativeAuthor | 강진한 | - |
dc.contributor.AlternativeAuthor | 홍영진 | - |
dc.contributor.AlternativeAuthor | 김윤경 | - |
dc.contributor.AlternativeAuthor | 정희진 | - |
dc.contributor.AlternativeAuthor | 안영주 | - |
dc.contributor.AlternativeAuthor | 김상훈 | - |
dc.contributor.AlternativeAuthor | 이환종 | - |
dc.identifier.doi | 10.1016/j.vaccine.2010.06.060 | - |
dc.citation.journaltitle | VACCINE | - |
dc.description.citedreference | Nolan T, 2010, JAMA-J AM MED ASSOC, V303, P37, DOI 10.1001/jama.2009.1911 | - |
dc.description.citedreference | Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2 | - |
dc.description.citedreference | Liang XF, 2010, LANCET, V375, P56, DOI 10.1016/S0140-6736(09)62003-1 | - |
dc.description.citedreference | JHUNG M, 2010, MMWR-MORBID MORTAL W, V59, P423 | - |
dc.description.citedreference | Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535 | - |
dc.description.citedreference | Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413 | - |
dc.description.citedreference | Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453 | - |
dc.description.citedreference | Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810 | - |
dc.description.citedreference | FIORE AE, 2009, MMWR-MORBID MORTAL S, V58, P1 | - |
dc.description.citedreference | *WHO, 2009, WKLY EPIDEMIOL REC, V84, P249 | - |
dc.description.citedreference | *WHO, 2009, PAND H1N1 2009 UPD 1 | - |
dc.description.citedreference | *CDCP, 2009, MMWR-MORBID MORTAL W, V58, P1100 | - |
dc.description.citedreference | *VACC REL BIOL PRO, 2009, REG CONS REG US NOV, P11601 | - |
dc.description.citedreference | *NAT I ALL INF DIS, 2009, YOUNG CHILDR 2 DOS 2 | - |
dc.description.citedreference | *CDCP, 2009, ESET 209 H1N1 INFL C | - |
dc.description.citedreference | *KOR CTR DIS CONTR, 2009, SURV DAT WEEK 52, P52 | - |
dc.description.citedreference | Talbot HK, 2008, VACCINE, V26, P4057, DOI 10.1016/j.vaccine.2008.05.024 | - |
dc.description.citedreference | *US FDA, 2007, GUID IND CLIN DAT NE | - |
dc.description.citedreference | *US FDA, 2007, GUID IND TOX GRAD SC | - |
dc.description.citedreference | Neuzil KM, 2006, J INFECT DIS, V194, P1032 | - |
dc.description.citedreference | Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795 | - |
dc.description.citedreference | ENGLUND JA, 2006, PEDIATRICS, V118, P579 | - |
dc.description.citedreference | Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025 | - |
dc.description.citedreference | Ruben FL, 2004, CLIN INFECT DIS, V38, P678 | - |
dc.description.citedreference | Neuzil KM, 2001, PEDIATR INFECT DIS J, V20, P733 | - |
dc.description.citedreference | *COMM PROP MED PRO, 1997, CPMPBWP21496 EUR AG | - |
dc.description.citedreference | KENDAL AP, 1982, CONC PROC LAB BAS IN | - |
dc.description.citedreference | PARKMAN PD, 1977, J INFECT DIS, V136, pS722 | - |
dc.description.citedreference | FOY HM, 1976, J INFECT DIS, V134, P362 | - |
dc.description.tc | 10 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.